Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Non-Current Liabilities: 2020-2022

Historic Total Non-Current Liabilities for Kymera Therapeutics (KYMR) over the last 3 years, with Dec 2022 value amounting to $112.7 million.

  • Kymera Therapeutics' Total Non-Current Liabilities rose 25.14% to $156.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $156.8 million, marking a year-over-year increase of 25.14%. This contributed to the annual value of $112.7 million for FY2022, which is 22.89% down from last year.
  • As of FY2022, Kymera Therapeutics' Total Non-Current Liabilities stood at $112.7 million, which was down 22.89% from $146.2 million recorded in FY2021.
  • In the past 5 years, Kymera Therapeutics' Total Non-Current Liabilities registered a high of $203.2 million during FY2020, and its lowest value of $112.7 million during FY2022.
  • For the 3-year period, Kymera Therapeutics' Total Non-Current Liabilities averaged around $154.0 million, with its median value being $146.2 million (2021).
  • Data for Kymera Therapeutics' Total Non-Current Liabilities shows a maximum YoY decreased of 28.05% (in 2021) over the last 5 years.
  • Over the past 3 years, Kymera Therapeutics' Total Non-Current Liabilities (Yearly) stood at $203.2 million in 2020, then declined by 28.05% to $146.2 million in 2021, then decreased by 22.89% to $112.7 million in 2022.